HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 02-14-2006, 09:07 AM   #1
Lani
Guest
 
Posts: n/a
the Soy story continues to be complicated...

All: 1 Review: 0

1: Bone. 2006 Feb 7; [Epub ahead of print] Related Articles, Links

Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model.

Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU.

Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, 150 College St. Toronto, Ontario, Canada M5S 3E2.

The use of phytoestrogens, such as isoflavones and lignans, for treatment of postmenopausal breast cancer is increasing, but their effects on bone and other major organs are not clear. While the isoflavone genistein (GEN) has been shown to prevent or slow the loss of bone mineral density (BMD), the effect of lignans enterodiol (END) and enterolactone (ENL) are unknown. In this study, we determined in ovariectomized mice with human MCF-7 breast tumor xenografts the effects of the lignans, and GEN, alone and in combination, on bone and uterus. Mice with established MCF-7 tumors were fed a basal diet (AIN-93G), divided into 5 groups, and given daily subcutaneous injections (10 mg/kg body weight) of either ENL, END, GEN, a mixture of these compounds (MIX), or vehicle as a negative control for 22 weeks. Results showed that GEN acts estrogenically in both the uterus and bone by increasing the uterus weight, femur BMD, and femur biomechanical strength (yield load), while the lignans do not. However, treatment with MIX induced minimal effects on femur biomechanical strength parameters but significantly increased uterus weight. A significant positive correlation was observed between MCF-7 tumor volume and femur BMD and biomechanical strength parameters (femur peak load and yield load) but not with uterus weight, suggesting that the uterus may respond differently to phytoestrogens compared to MCF-7 tumors and bone. It is concluded that GEN induces beneficial effects on bone but has adverse effects on tumors and uterus in this model of postmenopausal breast cancer. The lignans do not exert adverse effects on any tissue, however, when combined with GEN, they exert an adverse effect on the uterus.

PMID: 16469549 [PubMed - as supplied by publisher]
  Reply With Quote
Old 02-14-2006, 09:14 AM   #2
Lani
Guest
 
Posts: n/a
more complication

but remember all of these studies I posted so far are on her2 negative breast cancer cell lines...
: Br J Nutr. 2006 Feb;95(2):406-413. Related Articles, Links

Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines.

Caetano B, Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ.

Departement d'Oncogenetique du Centre Jean Perrin, INSERM UMR 484-UdA, Centre Biomedical de Recherche et de Valorisation, 28 place Henri Dunant, B.P.38, 63 001 Clermont-Ferrand Cedex 01, France.

Breast cancer is the most common cancer in women and a significant cause of death. Mutations of the oncosuppressor genes BRCA1 and BRCA2 are associated with a hereditary risk of breast cancer, and dysregulation of their expression has been observed in sporadic cases. Soya isoflavones have been shown to inhibit breast cancer in studies in vitro, but associations between the consumption of isoflavone-containing foods and breast cancer risk have varied in epidemiological studies. Soya is a unique source of the phytoestrogens daidzein (4',7-dihydroxyisoflavone) and genistein (4',5,7-trihydroxyisoflavone), two molecules that are able to inhibit the proliferation of human breast cancer cells in vitro. The aim of the present study was to determine the effects of genistein (5 mug/ml) and daidzein (20 mug/ml) on transcription in three human breast cell lines (one dystrophic, MCF10a, and two malignant, MCF-7 and MDA-MB-231) after 72 h treatment. The different genes involved in the BRCA1 and BRCA2 pathways (GADD45A, BARD1, JUN, BAX, RB1, ERalpha, ERbeta, BAP1, TNFalpha, p53, p21(Waf1/Cip1), p300, RAD51, pS2, Ki-67) were quantified by real-time quantitative RT-PCR, using the TaqMan method and an ABI Prism 7700 Sequence Detector (Applied Biosystems). We observed that, in response to treatment, many of these genes were overexpressed in the breast cancer cell lines (MCF-7 and MDA-MB-231) but not in the dystrophic cell line (MCF10a).

PMID: 16469160 [PubMed - as supplied by publisher]
  Reply With Quote
Old 02-14-2006, 09:47 AM   #3
RhondaH
Senior Member
 
RhondaH's Avatar
 
Join Date: Sep 2005
Location: Grand Rapids, MI
Posts: 1,516
Lani, heres one I found regarding soy and the

bc cell line BT-474.

http://undergradresearch.missouri.ed...?abstractid=15

Rhonda
RhondaH is offline   Reply With Quote
Old 02-23-2006, 11:07 PM   #4
Rich
Guest
 
Posts: n/a
If possible..for me it would be nice when cruising the site to have people's sense of what the article suggests. I know it's not always the case but often a sentence can boil down mucho medspeak and help us all keep a general tab on what's going on.
not a criticism, just a suggestion.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 06:00 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter